Q3 2024 Earnings Call Transcript November 7, 2024 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

ClearPoint Neuro develops and commercializes platforms for performing minimally invasive surgical procedures in the brain.

Deep Brain Stimulator MarketThe global deep brain stimulator market, valued at USD 1308.0 Million in 2024, is projected to grow steadily, reaching USD  2772.1 billion by 2034. With an anticipated CAGR ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter.

Neurological disorders are disorders that affect the central nervous system or the peripheral nervous systems and can impair the brain, spinal cord, peripheral nerve or neuromuscular function. A ...

(Update: Medtronic announced FDA approval for its Affera cardiac mapping and ablation system with the Sphere-9 catheter in October 2024.) Medtronic acquired the Sphere-9 catheter for pulsed field ...

and neurological disorders, while its top clients are hospitals, healthcare providers, and government healthcare programs. The most recent quarter saw Medtronic increase its total revenue by 5.3% YoY.

Medtronic PLC investors have been content with receiving dividends on their holdings for a few years now. The stock has ...

He originally joined Medtronic in 1991 with the title of marketing manager for Western Europe’s neurological business. ten Hoedt retired from his post at the medtech giant earlier this year.